HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.

Abstract
Antibiotic penetration to the infection site is critical for obtaining a good clinical outcome in patients with ventilator-associated pneumonia (VAP). Surprisingly few studies have quantified the penetration of β-lactam agents into the lung, as measured by the ratio of area under the concentration-time curve (AUC) in epithelial lining fluid (ELF) to AUC in plasma (AUC(ELF)/AUC(plasma) ratio). These have typically involved noninfected patients. This study examines the penetration and pharmacodynamics of meropenem in the ELF among patients with VAP. Meropenem plasma and ELF concentration-time data were obtained from patients in a multicenter clinical trial. Concentration-time profiles in plasma and ELF were simultaneously modeled using a three-compartment model with zero-order infusion and first-order elimination and transfer (big nonparametric adaptive grid [BigNPAG]). A Monte Carlo simulation was performed to estimate the range of ELF/plasma penetration ratios one would expect to observe in patients with VAP, as measured by the AUC(ELF)/AUC(plasma) ratio. The range of AUC(ELF)/AUC(plasma) penetration ratios predicted by the Monte Carlo simulation was large. The 10th percentile of lung penetration was 3.7%, while the 90th percentile of penetration was 178%. The variability of ELF penetration is such that if relatively high ELF exposure targets are required to attain multilog kill or resistance suppression for bacteria like Pseudomonas aeruginosa, then even receiving the largest licensed dose of meropenem with an optimal prolonged infusion may not result in target attainment for a substantial fraction of the population.
AuthorsT P Lodise, F Sorgel, D Melnick, B Mason, M Kinzig, G L Drusano
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 55 Issue 4 Pg. 1606-10 (Apr 2011) ISSN: 1098-6596 [Electronic] United States
PMID21300830 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
Chemical References
  • Anti-Bacterial Agents
  • Thienamycins
  • Meropenem
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (pharmacokinetics, therapeutic use)
  • Area Under Curve
  • Body Fluids (metabolism)
  • Chromatography, Liquid
  • Female
  • Humans
  • Male
  • Meropenem
  • Middle Aged
  • Monte Carlo Method
  • Pneumonia, Ventilator-Associated (drug therapy, metabolism)
  • Pseudomonas Infections (drug therapy, metabolism)
  • Tandem Mass Spectrometry
  • Thienamycins (pharmacokinetics, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: